1276.HK 600276.SHG
Legend Biotech is a biotech

Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) said on Sunday that executive director and senior vice president Sun Jieping will sell up to 476,700 of his A-shares in the company for personal reasons. Hengrui said Sun, who is the company’s deputy general manager, will sell the stock via centralized bidding during the three months starting 15 trading days after the disclosure.

Sun holds about 1.9 million Hengrui shares, accounting for roughly 0.029% of its total share capital, predominantly acquired through equity incentive plans. His planned sale represents about 0.007% of the company’s total share capital.

Hengrui is listed in Shanghai and made a second listing in Hong Kong at the end of last month. The offering was oversubscribed by about 454 times, with the international portion oversubscribed by 16 times. It priced its Hong Kong shares at HK$44.05 each, raising nearly HK$10 billion ($1.27 billion).

Shares of Hengrui opened down 0.5% at HK$57.50 on Monday. The stock is up around 30% from its Hong Kong listing price.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Yalla is a gaming company

Yalla kicks off new chapter with new midcore games

The Middle Eastern social media and gaming company plans to launch its first two midcore games this quarter, with another self-developed ‘roguelike game’ to follow Key Takeaways: Yalla revealed it…
Fu Shou Yuan does funeral memorial services

Slowing economy haunts undertaker Fu Shou Yuan

China’s top funeral services provider fell into the red in the first half of this year, extending a year of revenue and profit declines in 2024 Key Takeaways: Fu Shou…
Wynn Macau bets on concerts

Wynn Macau bets on concerts as a winning strategy

After missing the mark with its quarterly earnings, the Macao casino operator is building a big entertainment complex as an added draw for tourists Key Takeaways: Disappointing gaming results from…